Amyotrophic lateral sclerosis: current practice and future treatments
- PMID: 20613515
- DOI: 10.1097/WCO.0b013e32833c7ac2
Amyotrophic lateral sclerosis: current practice and future treatments
Abstract
Purpose of review: Knowledge of amyotrophic lateral sclerosis, and in particular the care of patients with it, is evolving exponentially. More than 1700 articles with the phrase 'amyotrophic lateral sclerosis' have been published in the past 2 years; these form the basis for this timely review.
Recent findings: In part 1, I give an update on the care of patients with amyotrophic lateral sclerosis, including ways to speed diagnosis, optimal use of riluzole, multidisciplinary teams, mechanical ventilation, gastrostomy tubes, lipid-lowering agents and symptom management. Although care has become more evidence-based, there remain a number of quandaries; for these, I will provide suggestions based upon my own experience. In part 2, I identify some exciting new treatment options that are under study. These include agents designed for novel targets within motor neurons and nonneuronal cells, agents designed for specific amyotrophic lateral sclerosis subtypes and interesting new technologies. Finally, in part 3, I define current barriers to developing even better therapeutics and offer ways around them.
Summary: The care of patients with amyotrophic lateral sclerosis has evolved and is now more evidence-based than ever before. Exciting new therapies are currently being tested, which may revolutionize care even further. Barriers exist, but they are surmountable.
Similar articles
-
Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).Amyotroph Lateral Scler Other Motor Neuron Disord. 2003 Sep;4(3):191-206. Amyotroph Lateral Scler Other Motor Neuron Disord. 2003. PMID: 13129806 Review.
-
Clinical care of patients with amyotrophic lateral sclerosis.Lancet Neurol. 2007 Oct;6(10):913-25. doi: 10.1016/S1474-4422(07)70244-2. Lancet Neurol. 2007. PMID: 17884681 Review.
-
[Amyotrophic lateral sclerosis. Fatal diagnosis -- how still can be helped?].MMW Fortschr Med. 2004 Nov 18;146(47):16. MMW Fortschr Med. 2004. PMID: 15624649 German. No abstract available.
-
Toward more efficient clinical trials for amyotrophic lateral sclerosis.Amyotroph Lateral Scler. 2010 May 3;11(3):259-65. doi: 10.3109/17482960903358865. Amyotroph Lateral Scler. 2010. PMID: 19961263 Review.
-
Outcome of sporadic amyotrophic lateral sclerosis treated with non-invasive ventilation and riluzole.Medicina (B Aires). 2007;67(4):326-30. Medicina (B Aires). 2007. PMID: 17891927 Clinical Trial.
Cited by
-
Associations between co-medications and survival in ALS-a cohort study from Austria.J Neurol. 2015 Jul;262(7):1698-705. doi: 10.1007/s00415-015-7767-7. Epub 2015 May 10. J Neurol. 2015. PMID: 25957641
-
Trophic factors as modulators of motor neuron physiology and survival: implications for ALS therapy.Front Cell Neurosci. 2014 Feb 28;8:61. doi: 10.3389/fncel.2014.00061. eCollection 2014. Front Cell Neurosci. 2014. PMID: 24616665 Free PMC article. Review.
-
Delayed administration of VEGF rescues spinal motor neurons from death with a short effective time frame in excitotoxic experimental models in vivo.ASN Neuro. 2012 Mar 27;4(2):e00081. doi: 10.1042/AN20110057. ASN Neuro. 2012. PMID: 22369757 Free PMC article.
-
Management of frontotemporal dementia: targeting symptom management in such a heterogeneous disease requires a wide range of therapeutic options.Neurodegener Dis Manag. 2011 Apr;1(2):141-156. doi: 10.2217/nmt.11.9. Neurodegener Dis Manag. 2011. PMID: 21927623 Free PMC article.
-
Medical management of frontotemporal dementias: the importance of the caregiver in symptom assessment and guidance of treatment strategies.J Mol Neurosci. 2011 Nov;45(3):713-23. doi: 10.1007/s12031-011-9558-7. Epub 2011 Jun 7. J Mol Neurosci. 2011. PMID: 21647712 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous
